Kawasaki Disease or Incomplete Kawasaki Disease Clinical Pathway — Emergency Department and Inpatient
Intravenous Immunoglobulin (IVIG)
- A multidisciplinary team of consultants with the primary team will discuss initiation of treatment and specific treatment interventions. Consults
- These discussions will be expedited in the setting of critical illness
- Monitor Clinical Response
- Resolution of fever, other clinical features and improving markers of inflammation
- Lack of clinical response: Further recommendations per Rheumatology and DIRT
Discuss Risks of Transfusion
- Occasional risks include: fever and allergic reactions due to the formation of antibodies
- Less common risks include: infections with viruses such as hepatitis, and fluid overload
- Risk of contracting infectious diseases from IVIG is extremely rare, IVIG is considered to be one of the safest blood products
- Written consent is no longer required for blood derived therapeutics such as IVIG
|Related Procedure/Policy/Job Aids||
- Transfusion. 2015 Jul: Suppl 2:S90-4. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease. Luban NL, Wong EC, Henrich Lobo R, Pary P, Duke S
- Asia Pac Allergy. 2013;3:249-256. Adverse events of intravenous immunoglobulin infusion: a ten-year retrospective study. Palabrica Frances Rose R, Kwong Shirley L., and Padua, Florecita R.
- Clin Exp Immunol. 1994; 97 (Suppl 1): 79-83. Side-effects of intravenous immune globulins. Duhem C, Dicato A, and Ries F.